Home  |  About SITC  |  Facebook  |  Twitter  |  LinkedIn  |  YouTube  |  Oncology Tube  |  Sitemap

Advances in Cancer Immunotherapy™ - Tampa, FL


Friday, December 5, 2014
8:00 am - 4:00 pm
Tampa, Florida
Tampa Marriott Waterside Hotel & Marina                                           
700 S. Florida Ave. 
Tampa, FL 33602

CME-certified regional program


Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
James J. Mulé, PhD – Moffitt Cancer Center
Vernon K. Sondak, MD – Moffitt Cancer Center

Planning Committee

Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists


Specifically designed for clinical oncologists and the entire medical team involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes. 

Attendees can also take advantage of the opportunity for professional networking that promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.

Intended Audience

The target audience for these programs includes clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics

  • Adjuvant Immunotherapy for High-Risk Melanoma:  Where Have We Been and Where Are We Going?
  • Adoptive T Cell Immunotherapy for Metastatic Melanoma
  • Checkpoint Inhibitors for Metastatic Melanoma
  • Combination Immunotherapies for Metastatic Melanoma:  What Agents and When?
  • Current Status of Immunotherapy for Kidney, Prostate and Bladder Cancer, Including Vaccines
  • Dual Role of the Immune System in Protection and Pathogenesis
  • Immune Escape – Targeting Immune Suppression as a Therapeutic Option
  • Immunology 101 for the Non-Immunologist
  • Immunotherapies for Lung Cancer
  • Melanoma Phenotypic Switching: Why Vaccines to Differentiation Antigens Don’t Work
  • Novel Gene Expression Signatures with Pathologic Correlates of Immune Reactivity
  • Oncolytic Virus Therapy in Cancer Immunotherapy: Brain Tumors
  • Radiation and Immune Therapy

Educational Objectives

Upon completion of this program, the participants should have been able to:

  • Interpret the key principles of tumor immunology and immunotherapy
  • Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
  • Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
  • Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy

Jointly provided by Clinical Immunology Society (CIS) and Society for Immunotherapy of Cancer (SITC)

The Advances of Cancer ImmunotherapyTM series is supported in part by educational grants from:

  • AstraZeneca
  • Bristol-Myers Squibb
  • Dendreon
  • Merck
  • Prometheus

To view all of SITC’s supporters, please, click here.

Society for Immunotherapy of Cancer
555 East Wells Street, Suite 1100  |  Milwaukee, WI 53202-3823 USA
Tel: +1 414 271 2456  |  Fax: +1 414 276 3349  |  Email: info@sitcancer.org
About SITC  |  Membership  |  Journal  |  Meetings  |  Resources  |  Support SITC
© 2016 Society for Immunotherapy of Cancer. All rights reserved.